Comparing US-China Colorectal Cancer Screening l BGI Perspectives

In recent years, cancer has become one of the major public health issues seriously threatening the Chinese population. According to the latest global cancer-related data for 2020 released by the International Agency for Research on Cancer (IARC) of the World Health Organization, 19.29 million new cancer cases and 9.96 million cancer-related deaths will occur.

The number of new cancer cases far exceeds that of other countries in the world. According to the latest data released by the National Cancer Center in 2022, China spends more than $220 billion on cancer-related medical treatment each year, and the overall 5-year survival rate of cancer in China is significantly worse than that of developed countries, making the prevention and control situation very serious.

Early cancer screening is an effective way to detect cancer and precancerous lesions at an early stage, playing a crucial role in the whole cycle of detection and treatment by screening out cancer-risk groups or cancer-positive patients from an asymptomatic population with fast and effective methods. Today, we will take colorectal cancer prevention and control and introduce U.S. and China’s developments in early screening for colorectal cancer.

Additional Readings:
https://www.twine.net/signin
https://www.twine.net/signin
https://www.twine.net/signin

About BGI Genomics:
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. BGI has topped the Asia Pacific and China life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables.
#bgichina #bgigenetest